Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal

Thymmune Therapeutics, a biotechnology company developing scalable thymic cell therapies to restore immune function in aging and disease, announced today that it has secured $7 million in seed financing. We congratulate the UCSF researchers, Matthias Hebrok, Mark Anderson, and Audrey Parent, on whose technology this company was built.